Navidea Biopharmaceuticals (NYSE:NAVB) said today that it inked a definitive asset purchase agreement with Cardinal Health (NYSE:CAH) for its Lymphoseek product. Dublin, Ohio-based Navidea said it’s due to receive $80 million at closing for the lymphatic mapping and lymph node biopsy product, plus the opportunity for $230 million in milestone payments through 2026. More than $20 […]
Mergers & Acquisitions
J&J approaches Actelion
Johnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the European biotech said there is no guarantee the deal will go through. J&J’s CEO Alex Gorsky said this year that the company is interested in deals […]
Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy
Allergan (NYSE:AGN) said today that it acquired Chase Pharmaceuticals for an upfront payment of $125 million, expanding the Dublin-based company’s neurological portfolio. Washington, D.C.-based Chase is developing a combination therapy of an acetylcholinesterase inhibitor and a cholinergic blocker in the hopes of improving cognition in patients with Alzheimer’s disease. The acetylcholinesterase inhibitors available on the […]
Vectura on the hunt for specialized lung drug business
(Reuters) — James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal. This time he’d like to buy a company with an established U.S. sales force to accelerate the group’s ambitions as it develops specialized lung drugs that are […]
